Table 4.
Correlation of wild-type or mutated PTCH1 with demographics, histological findings, and intrinsic subtype in 44 patients with breast cancer who underwent radical resection and standard adjuvant therapy.
| Wild-type PTCH1 | Mutated PTCH1 | p-value | |
|---|---|---|---|
| Patients, n (%) | 25 (57%) | 19 (43%) | |
| Age at surgery (years)* | 47 (31–75) | 50 (29–63) | 0.454 |
| Tumor size (cm)* | 2.8 (1.5–6.0) | 3.1 (1.4–8.0) | 0.648 |
| Nuclear grade | 0.710 | ||
| Grade II | 6 (67%) | 3 (33%) | |
| Grade III | 19 (54%) | 16 (46%) | |
| Extensive intraductal components | 8 (53%) | 7 (47%) | 0.759 |
| Lymphatic tumor emboli | 13 (52%) | 12 (48%) | 0.547 |
| Tumor-infiltrating lymphocytes | 0.058 | ||
| Low | 11 (79%) | 3 (21%) | |
| High | 14 (47%) | 16 (53%) | |
| Skin invasion | 2 (67%) | 1 (33%) | >0.999 |
| Nipple invasion | 3 (43%) | 4 (57%) | 0.432 |
| Axillary lymph node metastasis | 0.761 | ||
| Negative | 10 (53%) | 9 (47%) | |
| Positive | 15 (60%) | 10 (40%) | |
| Positive lymph node numbers | 1 (0–17) | 1 (0–43) | 0.853 |
| Total resected lymph node numbers | 19 (1–38) | 21 (5–45) | 0.297 |
| Extranodal extension | 3 (33%) | 6 (67%) | 0.257 |
| Nodal staging | 0.933 | ||
| N0 | 10 (53%) | 9 (47%) | |
| N1 | 8 (62%) | 5 (38%) | |
| N2 | 5 (63%) | 3 (37%) | |
| N3 | 2 (50%) | 2 (50%) | |
| Tumor stage | 0.906 | ||
| T1 | 2 (67%) | 1 (33%) | |
| T2 | 21 (57%) | 16 (43%) | |
| T3 | 2 (50%) | 2 (50%) | |
| AJCC TNM stage | 0.921 | ||
| Stage I | 2 (67%) | 1 (33%) | |
| Stage II | 16 (55%) | 13 (45%) | |
| Stage III | 7 (58%) | 5 (42%) | |
| Estrogen receptor | 0.361 | ||
| Negative (<10%) | 10 (48%) | 11 (52%) | |
| Positive (≥ 10%) | 15 (65%) | 8 (35%) | |
| Progesterone receptor | 0.474 | ||
| Negative (<10%) | 18 (53%) | 16 (47%) | |
| Positive (≥ 10%) | 7 (70%) | 3 (30%) | |
| Her-2/Neu | 0.124 | ||
| Negative | 12 (46%) | 14 (54%) | |
| Positive | 13 (72%) | 5 (28%) | |
| Intrinsic subtype | 0.192 | ||
| Luminal A | 6 (75%) | 2 (25%) | |
| Luminal B without Her-2/Neu overexpression | 2 (33%) | 4 (67%) | |
| Luminal B with Her-2/Neu overexpression | 7 (78%) | 2 (22%) | |
| Her-2/Neu overexpression | 5 (63%) | 3 (37%) | |
| Triple-negative breast cancer | 5 (38%) | 8 (62%) |
AJCC TNM stage, American Joint Committee on Cancer tumor-node-metastases (TNM) staging system, 7th ed.
*Values are expressed as median (range).